Elotuzumab: all 45 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingNCT06785415Phase 1/2
• Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMRecruitingNCT06518551Phase 1/2
• Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)TerminatedNCT04918147Phase 2Results posted
• Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedNCT03713294Phase 2Results posted
• Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideTerminatedNCT03411031Phase 2Results posted
• LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaCompletedNCT03361306Phase 2Results posted
• Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaActive, not recruitingNCT03030261Phase 2Results posted
• Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedNCT02969837Phase 2Results posted
• Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2Results posted
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)CompletedNCT02654132Phase 2Results posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in JapanCompletedNCT02272803Phase 2Results posted
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCompletedNCT02159365Phase 2Results posted
• PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TerminatedNCT01891643Phase 3Results posted
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01729091Phase 2Results posted
• S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple MyelomaCompletedNCT01668719Phase 1/2Results posted
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaCompletedNCT01632150Phase 2Results posted
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01478048Phase 2Results posted
• Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCompletedNCT01441973Phase 2Results posted
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCompletedNCT01393964Phase 1Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01335399Phase 3Results posted
• Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose DexamethasoneCompletedNCT01241292Phase 1Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01239797Phase 3Results posted
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaCompletedNCT00742560Phase 2Results posted
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesActive, not recruitingNCT05981209Phase 1
• A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05560399Early Phase 1
• Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaActive, not recruitingNCT05002816Phase 1/2
• Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous TransplantWithdrawnNCT04584307Phase 2
• Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisActive, not recruitingNCT04517851Phase 2
• Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MMActive, not recruitingNCT03948035Phase 3
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
• Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous GraftWithdrawnNCT03393273Phase 2
• 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
• Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment LinesCompletedNCT03155100Phase 2
• Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
• 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnNCT03003728Phase 2
• 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWithdrawnNCT03000634Phase 2
• Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedNCT02719613Phase 2
• A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingNCT02718833Phase 2
• Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple MyelomaCompletedNCT02655458Phase 1
• A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed MyelomaCompletedNCT02495922Phase 3
• Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT02420860Phase 2
• A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.TerminatedNCT00726869Phase 1
• Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple MyelomaCompletedNCT00425347Phase 1

← Elotuzumab overview